Faecalibacterium Prausnitzii Composition for IgE-Modulated Atopic Relief
Solution Overview
Problem
Current treatments for atopic diseases, such as atopic dermatitis, suffer from severe side effects and lack effective pharmaceutical efficacy, necessitating the development of new treatments that can balance Th1 and Th2 immune responses and reduce IgE secretion without adverse effects.
Innovation Solution
A pharmaceutical composition containing the Faecalibacterium prausnitzii EB-FPDK11 strain, which regulates immune responses and reduces IgE levels, is used to treat atopic diseases, formulated as oral and topical compositions, health foods, and cosmetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroid drugs are used for treating atopic diseases, then anti-inflammatory and immunosuppressive effects are improved, but side effects such as skin weakness, systemic hormonal symptoms, and addictive symptoms occur
Solution Approach 1:
The patent uses probiotic bacteria (Lactobacillus casei, Bifidobacterium animalis, Faecalibacterium prausnitzii) as temporary, self-limiting therapeutic agents that colonize the gut transiently to modulate immunity, avoiding the persistent systemic effects and addiction issues of steroids. These live bioactive substances work locally in the gut and are naturally eliminated, providing anti-inflammatory effects without long-term hormonal side effects.
Solution Approach 2:
The patent introduces probiotic bacteria as intermediary organisms that mediate between the gut environment and the immune system. These bacteria produce metabolites (short-chain fatty acids, bacteriocins) and interact with gut-associated lymphoid tissue to indirectly regulate systemic immunity, avoiding direct immunosuppression and its associated side effects while still achieving anti-inflammatory outcomes.
2Object-affected harmful factors
If antihistamines are used for reducing itching symptoms, then itching relief is improved, but side effects such as insomnia, anxiety and loss of appetite occur with long-term use
Solution Approach 1:
The patent employs probiotic bacteria as transient therapeutic agents that modulate the immune response underlying itching without causing CNS side effects. These bacteria work locally in the gut to reduce IgE production and regulate cytokine balance, providing itching relief through immune modulation rather than direct histamine blockade, thus avoiding insomnia and anxiety.
3Object-generated harmful factors
If new microbial drugs are used as alternative treatments, then side effects are reduced, but pharmaceutical efficacy is insufficient compared to conventional treatments
Solution Approach 1:
The patent combines multiple probiotic strains (Lactobacillus casei, Bifidobacterium animalis, Faecalibacterium prausnitzii) into a composite probiotic formulation, each strain contributing different immunomodulatory mechanisms. This synergistic combination enhances pharmaceutical efficacy through multiple pathways: L. casei reduces IgE, B. animalis regulates Th1/Th2 balance, and F. prausnitzii produces anti-inflammatory metabolites, collectively achieving steroid-level efficacy without side effects.
Solution Approach 2:
The patent optimizes key parameters of the probiotic formulation including bacterial cell counts (10^8-10^12 CFU per dose), storage conditions (-70°C or lyophilized), and administration regimens to maximize pharmaceutical efficacy. By controlling these parameters, the probiotic treatment achieves reliable clinical outcomes comparable to conventional drugs while maintaining the safety profile of live bioactive substances.
Data Source
AI summary
A pharmaceutical composition effective for the prevention or treatment of atopic disease is disclosed. The pharmaceutical composition contains a Faecalibacterium prausnitzii EB-FPDK11 strain or a culture or dried product thereof. While traditional probiotics generally have an insignificant therapeutic effect for atopic disease, the pharmaceutical composition of the present invention exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.